ADAR1 Capital Management LLC Makes New Investment in Stoke Therapeutics, Inc. $STOK

Key Points

• ADAR1 Capital Management LLC acquired 30,085 shares of Stoke Therapeutics, Inc. valued at approximately $200,000, representing about 0.06% of the company's stock as of its latest SEC filing.
• Stoke Therapeutics recently reported earnings of ($0.40) per share, exceeding analysts' expectations of (0.57) by $0.17, despite lower-than-expected revenue of $13.82 million.
• Analyst ratings for Stoke Therapeutics include a "buy" rating from two equities research analysts and several price targets, with the consensus price target currently at $25.57.

ADAR1 Capital Management LLC bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 30,085 shares of the company's stock, valued at approximately $200,000. ADAR1 Capital Management LLC owned 0.06% of Stoke Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after acquiring an additional 5,084 shares in the last quarter. AlphaQuest LLC acquired a new position in Stoke Therapeutics during the first quarter worth $72,000. US Bancorp DE raised its stake in Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after acquiring an additional 11,108 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in Stoke Therapeutics during the first quarter worth $92,000. Finally, Russell Investments Group Ltd. acquired a new position in Stoke Therapeutics during the first quarter worth $107,000.

Stoke Therapeutics Trading Up 7.7%

Stoke Therapeutics stock traded up $1.59 during mid-day trading on Monday, hitting $22.27. The stock had a trading volume of 508,997 shares, compared to its average volume of 805,994. The stock has a 50-day simple moving average of $14.92 and a two-hundred day simple moving average of $11.06. The stock has a market capitalization of $1.22 billion, a PE ratio of 26.12 and a beta of 1.14. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $22.39.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. The business had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. Sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 45,996 shares of the firm's stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total value of $925,899.48. Following the transaction, the director owned 91,585 shares in the company, valued at $1,843,606.05. This trade represents a 33.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 5,501 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total value of $109,304.87. Following the transaction, the insider owned 18,469 shares in the company, valued at approximately $366,979.03. This trade represents a 22.95% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 107,719 shares of company stock worth $2,063,359 over the last 90 days. Insiders own 9.50% of the company's stock.

Wall Street Analysts Forecast Growth

STOK has been the subject of several recent analyst reports. Wedbush increased their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Chardan Capital reiterated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. HC Wainwright lowered their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research note on Friday, July 18th. They issued a "buy" rating and a $30.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of "Buy" and an average target price of $25.57.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.